Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0001 USD | +9,900.00% | -.--% | -.--% |
2018 | Genoptix, Inc. cancelled the acquisition of Rosetta Genomics Ltd.. | CI |
2018 | Rosetta Genomics Ltd.(NasdaqCM:ROSG) dropped from NASDAQ Composite Index | CI |
Business Summary
Number of employees: 86
Sales per Business
USD in Million | 2015 | Weight | 2016 | Weight | Delta |
---|---|---|---|---|---|
MicroRNA-based Molecular Diagnostic
100.0
%
| 8 | 100.0 % | 9 | 100.0 % | +11.68% |
Sales per region
USD in Million | 2015 | Weight | 2016 | Weight | Delta |
---|---|---|---|---|---|
Israel and United States
100.0
%
| 8 | 100.0 % | 9 | 100.0 % | +11.68% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Ron Kalfus
DFI | Director of Finance/CFO | 50 | 23/05/12 |
Nicole Massoll
PRN | Corporate Officer/Principal | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
David Sidransky
BRD | Director/Board Member | 64 | 21/12/09 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 5,929,860 | 5,929,860 ( 100.00 %) | 0 | 100.00 % |
Company contact information
Rosetta Genomics Ltd.
10 Plaut Street Science Park
76706, Rehovot
+972 73 222 0700
Sector
1st Jan change | Capi. | |
---|---|---|
-.--% | 592 | |
+26.28% | 42.68B | |
-3.99% | 42.4B | |
+45.32% | 40.04B | |
-6.20% | 28.31B | |
+6.36% | 24.94B | |
-21.47% | 18.96B | |
+27.58% | 12.3B | |
-2.75% | 11.95B | |
-2.02% | 11.55B |
- Stock Market
- Equities
- ROSG.Q Stock
- Company Rosetta Genomics Ltd.